(Q40472879)

English

Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with speci

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with speci (English)

1 reference

Europe PubMed Central

20 September 2017

apoptotic process

0 references

1

1 reference

Europe PubMed Central

20 September 2017

author name string

Douwe F Samplonius

2

1 reference

Europe PubMed Central

20 September 2017

Linda van Genne

3

1 reference

Europe PubMed Central

20 September 2017

Marike H Dijkstra

4

1 reference

Europe PubMed Central

20 September 2017

Bart Jan Kroesen

5

1 reference

Europe PubMed Central

20 September 2017

Lou F M H de Leij

6

1 reference

Europe PubMed Central

20 September 2017

Wijnand Helfrich

7

1 reference

Europe PubMed Central

20 September 2017

language of work or name

0 references

publication date

11 January 2005

1 reference

Europe PubMed Central

20 September 2017

Journal of Biological Chemistry

1 reference

Europe PubMed Central

20 September 2017

280

1 reference

Europe PubMed Central

20 September 2017

10025-10033

1 reference

Europe PubMed Central

20 September 2017

11

1 reference

Europe PubMed Central

20 September 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

The ErbB receptors and their role in cancer progression.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Structural alterations of the epidermal growth factor receptor gene in human gliomas

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Pemetrexed: single-agent and combination phase I study overview

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

The receptor for the cytotoxic ligand TRAIL

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Caspase-10 is an initiator caspase in death receptor signaling

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP).

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

A dimeric bispecific miniantibody combines two specificities with avidity

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M413673200

21 January 2018

Identifiers

10.1074/JBC.M413673200

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40472879&oldid=1494892461"